B: Peg-interferon alpha-2a & Ribavirin — Competitive Intelligence Brief

B: Peg-interferon alpha-2a & Ribavirin (B: Peg-interferon alpha-2a & Ribavirin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination therapy. Area: Virology/Hepatology.

marketed Antiviral combination therapy Interferon-alpha receptor (IFNAR); Hepatitis C virus RNA-dependent RNA polymerase Virology/Hepatology Small molecule

Target snapshot

B: Peg-interferon alpha-2a & Ribavirin (B: Peg-interferon alpha-2a & Ribavirin) — Kaohsiung Medical University Chung-Ho Memorial Hospital. Peg-interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
B: Peg-interferon alpha-2a & Ribavirin TARGET	B: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); Hepatitis C virus RNA-dependent RNA polymerase
pegylated interferon alpha 2a, ribavirin	pegylated interferon alpha 2a, ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
Xenical, Pegasys, Copegus	Xenical, Pegasys, Copegus	Brooke Army Medical Center	marketed	Antiviral combination therapy (interferon + nucleoside analog); Lipase inhibitor	Hepatitis C virus NS5B polymerase; pancreatic lipase
Ganovo+ritonavir+/-Interferon nebulization	Ganovo+ritonavir+/-Interferon nebulization	The Ninth Hospital of Nanchang	marketed	Antiviral combination therapy	Viral RNA-dependent RNA polymerase; CYP3A4 (ritonavir); Interferon-alpha/beta receptors
D: Peg-interferon alpha-2a & Ribavirin	D: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
Peginterferon alfa-2a, Ribavirin, epoetin-β	Peginterferon alfa-2a, Ribavirin, epoetin-β	Germans Trias i Pujol Hospital	marketed	Antiviral combination therapy with hematopoietic agent	Interferon-α receptor; viral RNA polymerase; erythropoietin receptor
pegylated IFN alfa-2b plus ribavirin	pegylated IFN alfa-2b plus ribavirin	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); hepatitis C virus RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination therapy class)

1. Kaohsiung Medical University Chung-Ho Memorial Hospital · 6 drugs in this class
2. National Taiwan University Hospital · 6 drugs in this class
3. Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
4. Hepatitis Resource Network · 1 drug in this class
5. Hospices Civils de Lyon · 1 drug in this class
6. MTI Medical Private Limited, Pakistan · 1 drug in this class
7. Pacific Health Foundation · 1 drug in this class
8. RedHill Biopharma Limited · 1 drug in this class
9. Sherief Abd-Elsalam · 1 drug in this class
10. The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · 1 drug in this class